Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials

Written by: | no-reply@reuters.com | Dated: Sunday, June 11th, 2017

 

France’s Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.

Praluent significantly reduced low-density lipoprotein cholesterol in two phase 3b/4 Odyssey trials, the companies said in a joint statement.

 

(Reporting by Laurence Frost; Editing by Mark Potter)

 

Reuters source:

http://www.reuters.com/article/us-sanofi-fr-regeneron-pharms-study-idUSKBN1920V6

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2017 Focus: Payers, Biotech, HBA WOTY and more!

Subscribe

Ad Right Bottom

Main Navigation